INTRODUCTION AND OBJECTIVES:
Combining radiation with immune-checkpoint inhibitors was reported in some cancers to have synergic effects both locally and distally. Our aim was to assess this combined therapy on both radiated and non-radiated bladder tumors and to characterize the immune landscape within the tumor microenvironment.
METHODS: Murine bladder cancer cells (MB49) were injected s.c. in both flanks of C57BL/6 mice. Mice were randomly assigned to the following treatments: placebo, antiPD-L1 (4 intra-peritoneal injections over 2 weeks), radiation to right flank (10Gy in two fractions), or radiationþanti-PD-L1. Tumor digestion, flow cytometry, and qPCR were performed. Log-rank analysis was used for statistical significance.
RESULTS: RadiationþantiPD-L1 group demonstrated statistically significant slower tumor growth rate both in the radiated and nonirradiated tumors (p<0.001). Survival curves demonstrated superior survival in the combination group compared to each treatment alone (p[0.02). Flow cytometry showed increased infiltration of immunosuppressive cells as well as cytotoxic lymphocytes (CTL) in the radiation and combination groups (p[0.04). Ratio of immunosuppressive cells to CTL shifted in favor of cytotoxic activity in the combination arm (p<0.001). The qPCR analysis revealed downregulation of immunosuppressive genes (CCL22, IL22 and IL13), as well as upregulation of markers of CTL activation (CXCL9, GZMA and GZMB) within both the radiated and distant tumors within the combination group.
CONCLUSIONS: Combining radiation with immune checkpoint inhibitor provided better response in the radiated tumors and also the distant tumors along with a shift within the tumor microenvironment favoring cytotoxic activity. These findings demonstrate a novel abscopal effect in urothelial carcinoma with combination therapy.
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MP57-12 PYRUVATE DEHYDROGENASE KINASE 4 (PDK4) AS A NOVEL TARGET FOR SENSITIZING BLADDER CANCER TO CISPLATIN
Justin Penticuff*, Sambantham Shanmugam, Erika Abbott, Benjamin Woolbright, John Taylor, Kansas City, KS NTRODUCTION AND OBJECTIVES: PDK4 is a member of the PDK enzyme family which phosphorylate and inactivate the pyruvate dehydrogenase (PDH) complex, promoting aerobic glycolysis, known as the Warburg Effect. Studies indicate that this switch confers growth advantages as well as resistance to chemotherapy. We have previously reported substantial upregulation of PDK4 (33-fold) in high grade, invasive vs. low grade bladder cancers. We hypothesized that inhibition of PDK4 would reduce tumor growth both in vitro and in vivo and sensitize bladder cancer cells to cisplatin.
METHODS: Authenticated human high-grade bladder cancer cell lines HTB-9, HT-1376, HTB-5, and HTB-4 were utilized, as well as benign UROtsa cell lines. Animals were housed in a controlled environment with a 12-hour light/12-hour dark cycle and provided food and water ad lib. Pyruvate dehydrogenase (PDH) activity was performed using Sigma PDH Activity Assay (Sigma Aldrich). For the xenograft tumor gowth model, male nude mice (Crl nu/nu) were inoculated on right flank with 2 x106 HTB9 cells in a matrigel (5 mg/ mL) suspension (1:1). Treatment with DCA (200 mg/kg/day via oral gavage) and/or cisplatin (6 mg/kg intraperitoneal weekly). For the BBN (N-butyl-N-(4-hydroxybutyl)-nitrosamine) model, 4-5 week old C57Bl/6J mice were given 0.05% BBN in the drinking water for 16 weeks. At this point, normal water was returned and mice were put on treatment.
RESULTS: PDK4 was overexpressed in multiple bladder cancer cell lines. Treatment with dichloroacetate (DCA), a PDK 1-4 inhibitor, significantly increased PDH activity, reduced proliferation, and sensitized HTB-9 and HTB-5 cells to cisplatin induced cell death. Treatment of HTB-9 tumor xenografts with DCA or cisplatin did not reduce tumor volumes, however, co-treatment with both compounds resulted in significant reductions in viable tumor weights. PS10 (PDK2/4 inhibitor) treatment significantly increased PDH activity, sensitized UM-UC3 cells to cisplatin and reduced cellular proliferation. In the BBN model, PS10 alone had no effect. While cisplatin reduced bladder weights, only the PS10 plus cisplatin group resulted in a significant reduction in bladder tumor weight.
CONCLUSIONS: Inhibition of PDK4 sensitizes bladder cancers to cisplatin both in vitro and in multiple models in vivo, as well as having direct anti-proliferative effects in vitro. PDK inhibition may be a useful and novel way to enhance cisplatin based therapies in bladder cancer or directly target certain cancer subtypes. METHODS: One hundred and sixty paraffin-embedded UC tissues (130 bladder, 30 upper urinary tract) and 47 adjacent normal tissues were retrieved for IDO1 immunostaining. Urine samples from UC and non-UC patients were collected before surgery for measuring the concentration of tryptophan and its metabolites. Clinicopathological correlate of IDO1 expression and the prognostic values in human bladder cancer were explored. External validation was performed with 4 published bladder cancer datasets. The association between IDO1 and epithelial-mesenchymal-transition markers were explored from these 4 datasets and further in vitro cell studies were performed.
RESULTS: As compared with normal adjacent tissues, UC exhibited a higher frequency of IDO1 expression (chi-square, p[0.0005). There were a significantly lower urine tryptophan Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e817
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